BioMarin to acquire Amicus Therapeutics for $4.8 Billion
19/12/2025 12:50
Dec 19 (Reuters) - BioMarin Pharmaceutical BMRN.O said on Friday it will acquire Amicus Therapeutics FOLD.O in an all-cash deal worth about $4.8 billion. (Reporting by Christy Santhosh in Bengaluru; Editing by Leroy Leo) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on BioMarin Pharmaceutical
See all newsUS RESEARCH ROUNDUP-Analog Devices, IBM, Qualcomm
Brief: Biomarin Pharmaceutical Expects Q3 2026 Pre-Tax Charges Of $283 Million For Bought Ipr&D Expense
Brief: Biomarin Appoints Cara Bauer As Chief People Officer
Brief: Biomarin Pharmaceutical Enters Settlement And License Agreement With Ascendis Pharma On Sept 24, 2026
U.S. STOCKS ON THE MOVE-GitLab, California utilities, Herbalife